Screener
Gyre Therapeutics, Inc. GYRE Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Six Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|---|
| Operating Activities | |||
| Net (loss) income | $ | $$(32,849) | 2,702 |
| Adjustments to reconcile net (loss) income to net cash used in operating activities: | |||
| Stock-based compensation | 4,658 | 1,943 | |
| Equity in loss of unconsolidated affiliate | 43 | 38 | |
| Depreciation and amortization | 2,155 | 1,544 | |
| Noncash lease expense | 441 | 818 | |
| Deferred income taxes, net | (2,164) | (491) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s stock-based comp?
- Gyre Therapeutics, Inc. (GYRE) reported stock-based comp of $2.08M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Gyre Therapeutics, Inc.'s stock-based comp increased by 44.5% year-over-year, from $1.44M to $2.08M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s stock-based comp has grown at a 20.4% compound annual growth rate (CAGR), from $3.41M to $7.16M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Gyre Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude